Interpharma appoints Alfonso 'Chito' Zulueta as non-executive chairman
Interpharma Investments Limited, holding company of leading healthcare services provider Zuellig Pharma, announced the appointment of Alfonso “Chito” Zulueta as Non-Executive Chairman of its Board, effective 1 June 2023.
Zulueta succeeds Mr. Patrick Davies, who stepped down after serving as Non-Executive Chairman for four years. Zulueta joins Interpharma Investments Limited with more than three decades of experience with Eli Lilly and Company, where he was most recently President of Lilly International, and an Executive Committee member and Corporate Officer prior to his retirement in 2021. He has a strong track record in the pharmaceutical industry and extensive experience on corporate boards and industry associations. During his career with Eli Lilly and Company, he held both regional, U.S. and global roles across various functional areas including sales, marketing, product and business development, operations, and general management. "Zuellig Pharma plays a unique role in the healthcare landscape in Asia, as an innovative partner in many areas across distribution and commercialization solutions. With its rich, proven legacy and a spirit of resilience, entrepreneurship and depth, the company is well-placed for an exciting future. Patrick has been exceptional in helping steer the business through a solid period of growth. I look forward to continuing his legacy and contributing to the company's strategy to help achieve its mission of making healthcare more accessible in Asia," said Zulueta. He received a bachelor's degree in economics from De La Salle University in the Philippines in 1983 and a master's degree in business administration from the University of Virginia in 1987. He has held many board positions throughout his career, including chairman of the Japan-based Pharmaceutical Research and Manufacturers of America (PhRMA) from 2012–2013 Under the leadership of Davies, Zuellig Pharma overcame a period of uncertainty and significant challenges brought about by the pandemic, including major disruptions to supply chains and pressures on healthcare systems worldwide. Mr. Davies steered the company through an important business transformation, cementing its position as an indispensable partner to the company's key stakeholders and the communities it serves in Asia. Davies said, "The company's success in weathering massive challenges over the past four years is a true testament of our capabilities, collective resilience and commitment towards building a healthier future for Asia. It brings me great pride to have been part of this journey and I look forward to seeing Zuellig Pharma scale greater heights in the years to come." Interpharma Investments Limited expresses its sincerest gratitude to Davies for his valuable contribution to the Board during his four-year term and extends its warmest welcome to Zulueta. The company was started a hundred years ago and has grown to become an over US$15 billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.
Alfonso ‘Chito’ Zulueta
Zulueta succeeds Mr. Patrick Davies, who stepped down after serving as Non-Executive Chairman for four years. Zulueta joins Interpharma Investments Limited with more than three decades of experience with Eli Lilly and Company, where he was most recently President of Lilly International, and an Executive Committee member and Corporate Officer prior to his retirement in 2021. He has a strong track record in the pharmaceutical industry and extensive experience on corporate boards and industry associations. During his career with Eli Lilly and Company, he held both regional, U.S. and global roles across various functional areas including sales, marketing, product and business development, operations, and general management. "Zuellig Pharma plays a unique role in the healthcare landscape in Asia, as an innovative partner in many areas across distribution and commercialization solutions. With its rich, proven legacy and a spirit of resilience, entrepreneurship and depth, the company is well-placed for an exciting future. Patrick has been exceptional in helping steer the business through a solid period of growth. I look forward to continuing his legacy and contributing to the company's strategy to help achieve its mission of making healthcare more accessible in Asia," said Zulueta. He received a bachelor's degree in economics from De La Salle University in the Philippines in 1983 and a master's degree in business administration from the University of Virginia in 1987. He has held many board positions throughout his career, including chairman of the Japan-based Pharmaceutical Research and Manufacturers of America (PhRMA) from 2012–2013 Under the leadership of Davies, Zuellig Pharma overcame a period of uncertainty and significant challenges brought about by the pandemic, including major disruptions to supply chains and pressures on healthcare systems worldwide. Mr. Davies steered the company through an important business transformation, cementing its position as an indispensable partner to the company's key stakeholders and the communities it serves in Asia. Davies said, "The company's success in weathering massive challenges over the past four years is a true testament of our capabilities, collective resilience and commitment towards building a healthier future for Asia. It brings me great pride to have been part of this journey and I look forward to seeing Zuellig Pharma scale greater heights in the years to come." Interpharma Investments Limited expresses its sincerest gratitude to Davies for his valuable contribution to the Board during his four-year term and extends its warmest welcome to Zulueta. The company was started a hundred years ago and has grown to become an over US$15 billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.